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Abstract
The pathophysiology of chronic heart failure (CHF) involves multiple hystologic and molecular
alterations. To determine the effects of physical training on circulating endothelial progenitor
cells (EPCs), angiogenesis (angiogenin, angiopoietin-1 and -2, VEGF, Tie-2, SDF-1a) and
inflammation (IL-6, CRP), we compared data obtained from 11 CHF pts before and after
3 months aerobic exercise training, to those from 10 non trained CHF pts (CHF-C group, age
64þ 2 years, NYHA 2). At the end of the study, EPCs count and AP-2 serum levels significantly
increased in the CHF-TR group. These preliminary data suggest a significant effect of even a
short program of physical training on angiogenic activation and endothelial dysfunction.
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Introduction
The pathophysiology of chronic heart failure (CHF) is
exceptionally complex, involving multiple functional, ana-
tomic, histologic and molecular alterations at both cardiac and
peripheral level. The interplay between symptoms of CHF
and the activation of the immune and inflammatory systems,
together with the increase of oxidative and nitrosative stress,
is currently under intensive investigation at both experimental
and clinical level. Starting from the observation that
nitrotyrosine (NT), total nitric oxide (NO) and nitrite
plasma levels are increased in CHF in step with increasing
severity (Eleuteri et al., 2009a,b; Hare & Stamler 2005),
oxidative/nitrosative stress has been linked to endothelial
dysfunction and progressive deterioration of myocardial
performance in CHF patients (Bradley et al., 1993; Cai,
2005; Cai & Harrison, 2000). Reactive oxygen species (ROS)
can induce the expression of inflammatory cytokines; recip-
rocally, cytokines (particularly TNFa) may promote the
production of ROS (Adams et al., 2002; Mann & Reid,
2003; Tendera & Wysocki, 1999). ROS derived from
NAD(P)H oxidase are critically important for vascular
endothelial growth factor (VEGF) signaling in vitro and
angiogenesis in vivo (Ushio-Fukai et al., 2002). Nonetheless,
some kind of reciprocity has been reported between NO and
VEGF: NO may stimulate VEGF expression, while activation
of VEGF receptor-2 mobilizes intracellular calcium and
stimulates NO production (Ettington, 2009). All together,
these findings suggest the existence of a cross-talk between
inflammation, oxidative/nitrosative stress and angiogenesis
(Fiedler, 2006): its potential role in the pathophysiology of
CHF is, however, still unclear.
The progression from left ventricular dysfunction to the
complex CHF syndrome invariably leads to an increasing
deterioration of functional capacity. Since a personalized
exercise training program can significantly contribute to
interrupt and sometimes even reverse this unfavourable loop,
the bio-humoral modifications induced by exercise in stable
CHF patients are currently the object of evaluation and
scientific speculation. Beneficial effects of physical training
on different progenitor cells have previously been reported
(Laufs et al., 2004; Van Craenenbroeck et al., 2010). Regular
aerobic physical training has the potential to improve
endothelial dysfunction both in healthy individuals
(DeSouza et al., 2000) and in a pathological setting
(Hambrecht et al., 1998), but data on its effect on angiogenic
activation are scant. We recently reported that angiopoietin-2
(ang2) serum levels are elevated in CHF, showing a stepwise
increase of ang2, Tie-2 and VEGF in patients with CHF of
increasing severity (Eleuteri et al., 2011). The aim of this pilot
study was to evaluate the potential effects of a short exercise
training program on key markers of systemic inflammation
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and endothelial dysfunction, and to compare them to selected
markers of angiogenesis in a small series of selected clinically
stable patients with CHF due to moderate-to-severe left
ventricular systolic dysfunction. In addition, we sought to
analyze the behaviour of Endothelial Progenitor Cells (EPCs),
as a marker of endothelial damage/dysfunction, and of the
stromal cell-derived factor-1a (SDF-1a) levels, as a factor
potentially able to modify progenitor cell mobilization.
Method
Study population
The study was designed as a randomized, controlled,
prospective pilot study. Twenty-one male patients with CHF
were studied. Patients’ demographic, clinical and instrumental
characteristics are reported in Table 1. Selection criteria were
as follows: (1) CHF due to ischemic or idiopathic dilated
cardiomyopathy; (2) NYHA class II with stable medications
and no exacerbation of symptoms during the preceding
6 months; (3) echocardiographic left ventricular ejection
fraction (LVEF) 40%; (4) ramp incremental cardiopulmon-
ary exercise test stopped for fatigue and/or dyspnea with
ventilatory anaerobic threshold (VAT) identification and peak
respiratory exchange ratio of 1.10; (5) absence of angor and/
or instrumentally inducible myocardial ischemia and/or
evidence of complex ventricular arrhythmias. The study was
carried in conformity with the Declaration of Helsinki. The
protocol was approved by the Central Ethics Committee of the
Salvatore Maugeri Foundation and informed written consent
was obtained from all participants in the study.
Study scheme and training protocol
Baseline and end-protocol evaluations included: (a) complete
echocardiographic and Doppler examination; (b) brachial
artery flow-mediated dilation (FMD) by echo; (c) one ramp
incremental cardiopulmonary exercise test; (d) evaluation of
biomarkers and total progenitor endothelial cells in the serum
and blood.
After enrolment in the study, patients were randomly
assigned to either 3-month aerobic training (CHF-TR)
performed at home, or control (CHF-C). Each CHF-TR
patient was equipped by our Institution with a calibrated cycle
ergometer (Monark 915E; Monark Exercise AB, Stockholm,
Sweden), which they returned at the end of the study. The
training protocol consisted of 5 sessions a week of 30-min
cycle ergometry (60 rev/min) at a power and heart rate
corresponding to VAT, preceded and followed by a 5-min
warm-up and cool-down unloaded period, respectively. A
ramp incremental cardiopulmonary exercise test was repeated
6 weeks after the start of the study, in order to adjust training
stimulus intensity. To monitor both adherence to the training
prescription and arrhythmic incidence during exercise, CHF-
TR patients received a portable electrocardiograph (CG-2206;
Card Guard AG, Neuhausen am Rheinfall, Switzerland) able
to record up to 6 one-lead ECG traces and to transfer them
off-line by phone to a receiving station at our institution.
Patients were asked to record the ECG trace during the warm-
up, training, and cool-down phases of at least 3 sessions a
week; recordings were then transferred to the receiving
station at the end of the training session. CHF-C patients were
prescribed no formal training protocol, but simply instructed
to continue their normal lifestyle activities. The study design
did not allow a crossover of sedentary control patients to
exercise or vice versa.
Ergometric evaluation
All tests were performed on a cycle ergometer (Ergo-metrics
800S; Sensormedics, Yorba Linda, CA). After a 1-min
unloaded-cycling warm-up period, a ramp protocol of 10 W/
min (CHF-TR and CHF-C) or 15 W/min (N) at a pedaling rate
of 60 revs/min was started and participants were encouraged
to exercise until exhaustion. Respiratory gas exchange meas-
urements were obtained breath-by-breath using a computer-
ized metabolic cart (Vmax29; Sensormedics, Yorba Linda,
CA). Peak VO2 was the mean VO2 value observed during the
last 30 s of the exercise period. Predicted VO2max was
determined using a sex-, age-, and protocol-specific formula
defined by Wasserman et al. (2005), and VAT was estimated
by the V-slope and/or respiratory equivalents methods
(Wasserman et al., 2005).
Echocardiography and brachial artery endothelium-
dependent vasodilatation evaluation
At enrolment, all subjects underwent complete echocardio-
graphic and echo-Doppler evaluation by a single and
experienced operator (EE), unaware of the patient assignment
to the Control or Training group. The examination was
repeated at the end of the study. Left ventricular volumes
(LVV) were calculated from orthogonal apical views using
the biplane area-length method, and ejection fraction
(LVEF%) was derived from the standard equation. Intra-
observer variability for LVV and LVEF% was respectively
6 2 ml and 2 1%.
Table 1. Baseline demographic, clinical and instrumental characteristics
of control and trained CHF patients.
CHF-C (n¼ 10) CHF-T (n¼ 11) p (ANOVA)
Sex (M/F) 10/0 11/0 NS
Age (yrs) 63 2 66 2 NS
Weight (kg) 84 4 79 2 NS
NYHA class 2.2 0.1 2.3 0.1 NS
Peak VO2 (ml/kg/min) 16.7 0.4 14.8 0.7 NS
%Predicted VO2max 62 4 59 5 NS
VAT VO2 (ml/kg/min) 10.0 0.3 8.8 0.5 NS
LVEF (%) 30 1.8 28 2.1 NS
EDV/BSA (ml/mq) 103 10 117 12 NS
DecTime (ms) 196 14 189 14 NS
Bas-BA (cm) 0.43 0.01 0.44 0.02 NS
D%BA 7.7 1.4 5.1 0.7 NS
bB (%) 100 100 NS
ACE-inhibitors (%) 100 100 NS
Statins (%) 70 80 NS
Nitrates (%) 30 28 NS
Results expressed as mean standard error (SE).
Bas-BA¼ basal diameter of brachial artery; %BA¼% dilatation of
brachial artery; Peak VO2¼maximal oxygen consumption; %Predict.
VO2max¼ peak VO2 as percentage of predicted maximum;
VAT¼ventilatory anaerobic threshold; LVEF¼ left ventricular ejec-
tion fraction; EDV/BSA¼ end diastolic volume/body surface area;
DecT¼ deceleration time of early filling of the left ventricle;
bB¼ beta blockers.
ANOVA test was applied for comparative purposes.
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Endothelium-dependent FMD of the brachial artery (BA)
was determined with high-resolution ultrasound imaging
according to guidelines (Corretti et al., 2002), by a single
and experienced operator (EE). Brachial artery diameter was
determined as the mean of 5 measurements from a single
cardiac cycle at end-diastole in basal condition, and then 60 to
90 s after cuff release (forearm cuff occlusion maintained for
5 min). FMD was calculated as the per cent change in BA
diameter after forearm cuff release compared with the resting
BA diameter. BA blood flow velocity was determined placing
a 1.2 mm pulsed Doppler sampling volume in the vessel
lumen midline, with software correction for the incident angle
of 60 at rest and for the first 15 s after forearm cuff release.
The mean blood flow velocity over 5 cardiac cycles is
reported. The intra-observer variability was 1 0.4%.
Blood EPCs measurement
Whole peripheral blood samples were analyzed by flow
cytometry as previously described (Colombo et al., 2012;
Della Bella et al., 2008). Briefly, heparinized whole blood
samples (100mL) were incubated for 20 min at 4 C with
biotin-conjugated anti-human KDR (Sigma-Aldrich, St.
Louis, MO), phycoerythrin (PE)-conjugated anti-human
CD133 (Miltenyi-Biotec, GmbH, BergischGladbach,
Germany), Allophycocyanin (APC)-conjugated anti-human
CD34 (Beckman-Coulter Immunotech, Marsille, France) and
Peridinin-Chlorophyll-Protein Complex Cyanin 5.5 (PerCP-
Cy5.5)-conjugated and anti-human CD45 (BD Biosciences,
San Jose, CA) monoclonal antibodies (mAbs). After incuba-
tion, the erythrocytes were lysed, and the remaining cells
were washed with PBS, blocked with mouse serum (Dako)
and further incubated in the dark for 20 min with fluorescein
isothiocynate (FITC)-conjugated streptavidin (Sigma) to
reveal Biotin-conjugated anti-human KDR. Fluorescence
minus one (FMO) samples were used as negative controls.
Samples were analyzed immediately after staining using a
FACSCanto2 flow cytometer (BD), and FACSDiva-Software
(BD). An acquisition gate was established based on forward
scatter (FSc) and side scatter (SSc) that included mononuclear
cells (MNCs) but excluded most granulocytes and debris. In
all 300,000 events were routinely collected to visualize and
gate around this population. EPCs were identified as
CD45dimCD34þKDRþ cells, chosen as the preferable anti-
genic combination to define EPCs in terms of detection
accuracy, biological meaning and clinical usefulness
(Colombo et al., 2012; Della Bella et al., 2008). EPC count
was expressed as percentage of MNCs (Figure 1).
Serum collection and analysis
All patients underwent blood drawing after a 12-hour
nighttime fasting period, between 8:00 and 9:00 AM. Blood
samples were collected using Bekton Dikinson (BD)
Vacutainer Cat Plus REF 367896 for serum. Serum was
then aliquoted and immediately frozen at 80 C until
analysis. The serum levels of angiogenin, angiopoietin-1,
angiopoietin-2, VEGF, interleukin-6 (IL-6), C-reactive pro-
tein (CRP), SDF-1a and proBNP were determined by
commercially available enzyme linked immunosorbent assay
(ELISA) kits or routinely determined as described in Table 2.
Table 2 also shows the lower detection limits and the method
of quantification (ELISA, Modular Analytics) for each of the
molecules studied. Manufacturers’ instructions were carefully
followed for each of the ELISA kits used. Further details for
each kit are available from the respective online datasheet
(www.RnDSystems.com; www.roche.com).
Data analysis
Group data were expressed as mean standard error (SE)
for functional data or median (range) for serum levels or
blood EPCs data. Differences between groups were
analyzed using analysis of variance (ANOVA) for func-
tional data. The Wilcoxon test was applied for serum
biomarkers and blood EPCs for comparison between
baseline and end period data for each group. Spearman’s
correlation test was used to determine the association
between measured variables. Probability values of p50.05
were considered as significant. Data analysis was per-
formed using the Stat View SE Graphics program (Abacus
Concepts Inc., Berkeley, CA).
Results
Subjects
Baseline characteristics
Characteristics of the study population are summarized in
Table 1. Study groups were well matched for age and weight;
all patients were on optimized therapy with beta-blockers and
ACE-inhibitors with a minimal and stable dose of diuretics, at
least in the 3 months preceding the protocol (Table 1).
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Figure 1. Angiopoietin-2 serum levels (a) and % circulating peripheral
blood progenitor cells (b) in control and trained chronic heart failure
(CHF) patients at baseline and after a 3 months period of exercise
training. Data are expressed as mean SE.
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Both baseline peak incremental effort performance as
described by peak VO2, and VAT VO2 were similar at
baseline in CHF-TR and CHF-C groups (Table 1).
End-protocol characteristics
No adverse events occurred during training sessions in the
CHF-TR group; the actual training heart rate (monitored
trans-telephonically) was equal to 102 4% of prescribed
training heart rate during the whole protocol duration. The
percentage of non-adherence to the prescribed training
sessions was negligible (51%).
Echocardiographic parameters
No significant modification was found after 3 months in either
CHF-TR or CHF-C in EDV/BSA, LVEF%, or DecT.
Ergospirometric parameters
At the end of the study, peak VO2 and VAT VO2 increased
significantly by 9% (p¼ 0.01) and 14% (p¼ 0.009), respect-
ively, in CHF-TR but not in CHF-C (Table 3).
Endothelial dysfunction
At the end of the study, a significant improvement in
endothelial-mediated vasodilation of the brachial artery was
detected by echo in CHF-TR (5.1 0.7 % to 7.0 0.5 %,
p¼ 0.03) but not in CHF-C (Table 3).
Quantification of serum bio-markers and peripheral blood
progenitor cells
Quantification of angiogenin, VEGF, angiopoietin-1, SDF-1a,
pro-inflammatory markers IL-6, CRP and of NT-proBNP was
not statistically different in the CHF-C and CHF-TR patients
at end of study (T2) compared to baseline values (T1, see
Table 4), even though a tendency to SDF-1a increase was
observed in the CHF-C (p¼ 0.051, Table 4). While in the
CHF-C group both ang-2 and EPC did not show significant
modifications at T2 vs T1 (Table 4), they significantly
increased in the CHF-TR group (ang-2 from 2.7 to 3.2 ng/ml,
p¼ 0.007, EPC from 0.13 to 0.028, p¼ 0.025, see Table 4 and
Figure 1 for further details).
Correlations
In both control and trained patient groups, none of the
biomarkers studied nor the number of circulating progenitor
cells correlated significantly with LVEF% at echocardiog-
raphy, peak VO2, VAT VO2 or with any other functional
parameter. Furthermore, we did not observe a significant
correlation between ang-2 levels in the serum and numbers of
circulating progenitor cells.
Discussion
Endothelial dysfunction and EPC
Endothelial function is impaired in patients with CHF, and
has been associated with an increased mortality risk (Katz
et al., 2005). Regular physical exercise can improve both
endothelial dysfunction and exercise capacity in CHF patients
(DeSouza et al., 2000; Hambrecht et al., 1998). Due to its
potential to improve both peripheral and central components
of CHF in patients with left ventricular dysfunction, exercise
training is highly recommended by the European Society of
Cardiology (McMurray et al., 2012), but whether an improve-
ment (or, conversely, a lack of change) in endothelial
dysfunction following physical training may help identify
patients with different clinical outcomes remains unknown
Table 3. End-protocol instrumental values in control and trained CHF patients.
CHF-C baseline CHF-C end p CHF-T baseline CHF-T end p Value
Peak VO2 (ml/kg/min) 16.7 0.4 16 0.6 0.06 14.8 0.7 16.5 0.7 0.01
VAT VO2 (ml/kg/min) 10 0.3 9.1 0.5 0.10 8.8 0.5 10.1 0.5 0.009
LVEF (%) 30 1.8 31 2.5 0.29 28 2 28 2 0.31
EDV/BSA (ml/mq) 103 10 99 9 0.13 117 12 119 13 0.26
DecT (ms) 196 14 189 7 0.44 189 14 183 15 0.31
Bas-BA (cm) 0.44 0.01 0.44 0.02 0.86 0.44 0.01 0.43 0.01 0.36
D% BA 7.7 1.4 8.2 1.5 0.29 5.1 0.7 7 0.5 0.03
Results expressed as mean standard error (SE). Bas-BA¼ basal diameter of brachial artery; %BA¼% dilatation of brachial
artery; Peak VO2¼maximal oxygen consumption; VAT¼ventilatory anaerobic threshold; LVEF¼ left ventricular ejection
fraction; EDV/BSA¼ end diastolic volume/body surface area; DecT¼ deceleration time of early filling of the left ventricle;
Wilcoxon test was applied for comparative purposes.
Table 2. List of ELISA or routine determination tests for biomarkers included in the study.
Molecules Manufacturer (code) Lower detection limit Type of plasma/serum Analytical method
Angiogenin R&D Systems (DAN 00) 6.0 pg/ml serum ELISA
Angiopoietin-1 R&D Systems (DANG 10) 1.36 pg/ml serum ELISA
Angiopoietin-2 R&D Systems (DANG 20) 1.20 pg/ml serum ELISA
VEGF R&D Systems (DVE 00) 5.0 pg/ml serum ELISA
IL-6 R&D Systems (HS 600B) 0.039 pg/ml serum ELISA
CRP Roche Diagnostics (03002012 122) 0.42 pg/ml serum Modular Analytics
NT-ProBNP Roche Diagnostics (03121640 122) 5.0 pg/ml serum Modular Analytics
SDF-1a R&D Systems (DVE 00) 18.0 pg/ml EDTA ELISA
DOI: 10.3109/1354750X.2013.805342 Aerobic training and angiogenesis activation 421
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(Piepoli et al., 2010). The identification of EPCs in the
peripheral blood of adult healthy subjects as bone marrow-
derived cells with the features of a progenitor cell and
belonging to the endothelial lineage represented a crucial
breakthrough in the field of angiogenesis research (Asahara
et al., 1997). In recent heart failure models, EPC mobilization
appears to be stage dependent, with a progressive exhaustion of
progenitor cells in the advanced phases of the disease (Leone
et al., 2005); EPC levels are also reported as independent
predictors of all-cause mortality among patients with CHF
(Michowitz, 2007). Van Craenenbroeck et al. (2010) recently
demonstrated that a 6-month exercise training program can
increase both the migrating function of circulating angiogenic
cells (CACs) and the numbers of blood EPCs. In the present
study, as an original contribution, we demonstrate that even a
shorter training period of 3 months, performed at lower
intensity levels compared to the Van Craenenbroeck protocol,
is able to induce mobilization of EPCs, together with improv-
ing endothelial dysfunction and exercise aerobic capacity in
CHF patients. In fact, in our series of CHF patients, a 3-month
training program led to a significant increase in both peak VO2
and VAT VO2, respectively of 9% and 14%, together with a
statistically significant improvement in endothelial dysfunc-
tion, both in terms of increased FMD of the brachial artery by
echo (41% FMD increase at the end of training program versus
basal FMD) and of blood EPC count.
SDF-1 plays a critical role in the complex process of
selective migration and recruitment of EPCs during blood
vessel formation and repair. In ischemic tissues, the falling of
oxygen tension leads to increasing levels of hypoxia inducible
factor-1 (HIF-1), thus activating the transcription of SDF-1 by
endothelial cells in direct proportion to reduced oxygen
tension (Ceradini et al., 2004). In our series, SDF-1a plasma
levels remained stable in the training group, while they
slightly increased in the control group. This paradoxical
finding may be due to different and alternative roles played by
SDF-1: progenitor cell mobilization, chemoattraction for
lymphocytes, increase of B cell proliferation, immune
surveillance and, finally, homing of lymphocytes (Karin,
2010). All these functions are related to systemic inflamma-
tion; as reported in Table 4, a trend to increase of inflam-
matory markers was observed in the CHF-C group, in line
with the increase of SDF-1a levels. Though we do not have a
specific explanation for this finding, it seems to give more
reliability to the opposite trend of the same pro-inflammatory
markers in the CHF-TR group.
Inflammatory markers, NT-proBNP and angiogenic
markers in the peripheral blood
Physical training can possibly lead to modulation of pro-
inflammatory cytokines in patients with CHF (Adamopoulos
et al., 2002), though data are somewhat controversial (Smart
et al., 2011). In biopsies coming from skeletal muscle of
patients with CHF, a significant increase in both VEGF gene
expression (mRNA) and protein concentration has been
detected (Gustaffson, 2001), suggesting VEGF as one of the
possible mediators of exercise-induced angiogenesis in CHF.
In our series of trained CHF patients, we detected a trend to
decrease of IL-6, in line with a recent review by Smart (Smart
& Steele, 2011), but without reaching statistical significance.
All the same, we did not find any significant variation at
follow-up versus baseline in terms of VEGF, angiogenin,
angiopoietin-1 or NT-proBNP serum levels, either in the
CHF-C or CHF-TR group. But, as an original contribution, we
identified ang-2 as the only angiogenic cytokine that
Table 4. Baseline and End follow-up median values of biomarkers in the serum of control and trained CHF patients.
Biomarkers Subjects Baseline values End values Wilcoxon test
Angiogenin(ng/ml) Controls (n¼ 10) 383.9 (258–543) 366.8 (246–497) p¼ 0.37
Trained (n¼ 11) 392.9 (244–674) 371.7 (174–937) p¼ 0.72
VEGF (pg/ml) Controls (n¼ 10) 220.9 (83–646) 278.9 (124–664) p¼ 0.17
Trained (n¼ 11) 338.9 (88–839) 300.7 (88–1133) p¼ 0.29
Angiopoietin 1 (ng/ml) Controls (n¼ 10) 18.9 (3–49) 26.5 (9–54) p¼ 0.24
Trained (n¼ 11) 20.6 (8–29) 15.5 (3–31) p¼ 0.33
Angiopoietin 2 (ng/ml) Controls (n¼ 10) 2.6 (1–7) 2.7 (2–8) p¼ 0.39
Trained (n¼ 11) 2.7 (1–5) 3.2 (1–9) p¼ 0.007
CD45dimCD34þKDRþ (% mononuclear cells) Controls (n¼ 10) 0.012 (0.005–0.052) 0.019 (0.003–0.037) p¼ 0.44
Trained (n¼ 11) 0.013 (0.005–0.032) 0.028 (0.009–0.048) p¼ 0.025
IL-6 (pg/ml) Controls (n¼ 10) 0.9 (0.4–3.4) 1.0 (0.3–2.9) p¼ 0.26
Trained (n¼ 11) 2.3 (0.3–9.2) 1.9 (0.5–11.3) p¼ 0.62
CRP (mg/L) Controls (n¼ 10) 1.2 (0.8–8.9) 1.6 (0.6–27.9) p¼ 0.68
Trained (n¼ 11) 2.1 (0.3–6.9) 2.0 (0.4–10) p¼ 1.00
NT-proBNP (pg/ml) Controls (n¼ 10) 545.6 (62–3312) 609.1 (138–1910) p¼ 0.88
Trained (n¼ 11) 853 (87–3772) 1024.5 (85–3686) p¼ 0.57
SDF-1a (pg/ml) Controls (n¼ 10) 2549 (1756–3654) 2759 (2241–3931) p¼ 0.051
Trained (n¼ 11) 2868 (1628–3705) 2742 (1817–3894) p¼ 0.59
Results expressed as median (range).
VEGF¼ vascular endothelial growth factor; CRP¼C-reactive protein; IL¼ interleukin; NT-proBNP¼ brain natriuretic peptide; SDF-1a¼ stromal
cell-derived factor 1 alpha.
Wilcoxon text was applied for comparative purposes.
422 E. Eleuteri et al. Biomarkers, 2013; 18(5): 418–424
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significantly increased at the end of the training program
(Table 4 and Figure 1). The angiopoietin – Tie-ligand –
receptor system plays a key role in maintaining vascular
integrity and quiescence, and it is an important regulator in
numerous diseases. Ang-1-mediated Tie-2 activation is
required to maintain the quiescent resting state of the
endothelium, while ang-2 destabilizes the quiescent endothe-
lium and primes it to respond to exogenous stimuli, thereby
facilitating the activities of inflammatory (tumor necrosis
factors and interleukin-1) and angiogenic (VEGF) cytokines
(Fiedler & Augustin, 2006). As hypoxia itself does not
stimulate the expression of the endothelial survival factor
ang-1, some authors have hypothesized that ang-1 would not
be altered in CHF, and their experimental data, together with
our recent observations in humans (Eleuteri et al., 2011),
seem to confirm this hypothesis (Chong et al., 2004; Fiedler
& Augustin, 2006). On the contrary, a significant correlation
between ang-2 and partial pressure of oxygen in arterial
blood, and between ang-2 and tissue hypoxia has been
reported in a series of critically ill patients (Kumpers et al.,
2008). Ang-2 is expressed weakly by the resting endothelium,
but becomes strongly up-regulated following endothelial
activation; in the presence of VEGF, ang-2 promotes a
rapid increase in capillary diameter, remodeling of the basal
lamina and new vessel growth (Fiedler & Augustin, 2006). In
contrast, if VEGF is inhibited, ang-2 leads to endothelial cell
death and vessel regression.
While VEGF receptor expression is up-regulated by
exercise, exercise may not be translated into elevated VEGF
protein levels, suggesting that mobilization of VEGF content
from active muscles may be an important determinant of
improved muscle capillary supply (Ushio-Fukai et al., 2002).
This might explain the finding of stable serum levels of
VEGF in our trained CHF population, without excluding an
activation of pro-angiogenic molecules. In fact, the increased
plasma levels of pro-angiogenic cytokines, driven by tissue
hypoxia (Gustaffson et al., 2001), may be sufficient for
maintenance of endothelial function, as capillary density is
decreased in muscles of CHF patients, thus contributing to
reduced aerobic capacity (Duscha et al., 1999). As angio-
poietins are growth factors acting through a modulation of
vessel development and remodeling (Thurston, 2003), and
since the ratio of ang2/ang1 is further elevated after exercise
training (Lloyd et al., 2003), this might be consistent with the
promotion of capillary growth in the presence of VEGF (Lip
& Chung, 2005; Ushio-Fukai et al., 2002). However, in
humans, there are no studies clearly proving that angiogenesis
per se occurs in CHF. Recently Luk et al. (2009) failed to find
a significant correlation between physical activity levels
(PAL) and EPC count, suggesting that higher levels of
training, in terms of workload and duration of exercise, might
improve endothelial function through mechanisms other than
increasing the EPC count.
In our series of CHF trained patients we did not find a
direct correlation between EPC count and serum levels of
ang-2. The increased number of EPCs might not necessarily
be directly related to the increased pro-angiogenic stimulus
(this observation would be confirmed by the trend observed of
SDF-1a), even though both of them might contribute to the
functional improvement observed after the training program.
A possible limitation of our study could be that the
intensity and duration of the training program could have
affected the weight of the results that were obtained; as a
consequence, we might have missed some of the effects of
exercise in our series of CHF patients.
In conclusion, these preliminary results bring data in
support of an interrelationship between endothelial repair and
the activation of pro-angiogenic mechanisms occurring even
after a moderate and time-limited physical training program,
and they prompt us to better evaluate the functional and
biologic consequences of longer and stronger periods of
training in a wider population of stable CHF patients.
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